NCT01523392

A Pharmacodynamic Study With Ticagrelor in African American Patients

A Randomized, Open-Label, Multiple Dose, Crossover, Multiple Center Study of the Antiplatelet Effects of Ticagrelor Versus Clopidogrel in African American Patients With Stable Coronary Artery Disease

• Status: Completed
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 50 (actual)
• Sponsor: AstraZeneca · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to assess the pharmacodynamic effect of ticagrelor in African American patients with stable coronary artery disease.

Detailed description

A Randomized, Open-Label, Multiple Dose, Crossover, Multiple Center Study of the Antiplatelet Effects of Ticagrelor versus Clopidogrel in African American Patients with Stable Coronary Artery Disease

Conditions

• Stable Coronary Artery Disease

Interventions

Type	Name	Description
DRUG	Ticagrelor	Min - 90mg/Max - 180mg tablets (loading dose)
DRUG	Clopidogrel	75mg (once daily)/Max - 600mg tablets (loading dose)

Timeline

• Start date: 2012-03-01
• Primary completion: 2013-09-01
• Completion: 2013-09-01
• First posted: 2012-02-01
• Last updated: 2014-10-08
• Results posted: 2014-09-26

Locations

8 sites across 1 country: United States